Navigation Links
PTC Therapeutics Added to NASDAQ Biotechnology Index
Date:12/23/2013

SOUTH PLAINFIELD, N.J., Dec. 23, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), effective prior to the market open today.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities classified as either Biotechnology or Pharmaceuticals. These companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit https://indexes.nasdaqomx.com/.

About PTC Therapeutics, Inc.
PTC is biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and form the basis for collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com.

Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
2. Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors
3. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
4. BiOptix Continues Support of Antibody Engineering & Therapeutics Research
5. NKT Therapeutics Identifies Novel anti-iNKT Antibodies for Depleting or Activating iNKT Cells
6. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
7. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
8. Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
9. Scientists develop way to successfully give nanoparticle therapeutics orally
10. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
11. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... 2014 Robert Harman, DVM, Founder and CEO ... proud to announce the relaunch of his highly informative blog, ... series called “ What are Stem Cells ?” Dr. ... straightforward foundation in the basics of stem cell therapy so ... right type of treatment when considering regenerative medicine. , A ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Leader in, Animal Health and Strengthens Product Pipeline, Adding ... ... Projects, KENILWORTH, N.J., Nov. 19 Schering-Plough,Corporation (NYSE: ... BioSciences N.V., creating a stronger combined,company with broader human and animal ...
... discovery of a new way to manipulate light a million ... Science this week. , Using a special hollow-core photonic ... has opened the door to what could prove to be ... and trapping. , The team, led by Dr Fetah Benabid, ...
... The Committee for,Medicinal Products for Human Use ... (EMEA), granted Abbott (NYSE: ABT ) a ... treatment,of moderate to severe plaque psoriasis. Psoriasis will ... is a non-contagious, chronic autoimmune disease that causes,the ...
Cached Biology Technology:Schering-Plough Completes Acquisition of Organon BioSciences 2Schering-Plough Completes Acquisition of Organon BioSciences 3Schering-Plough Completes Acquisition of Organon BioSciences 4Schering-Plough Completes Acquisition of Organon BioSciences 5Discovery of a new way to manipulate light a million times more efficiently 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 3Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 4Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 5Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 6Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 7Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 8
(Date:7/10/2014)... , July 7, 2014 ... Market Research "Electronic Access Control Systems Market Global Forecast, ... 2019," the global Electronic Access Control systems market was ... expected to grow at a CAGR of 12.6% from ... USD 31,187.8 million in 2019. Browse the ...
(Date:7/10/2014)... The genus Axinaea belongs to the large, mainly ... the ca. 5000 species in the family rely on bees ... pollinated by other insects or vertebrates. The flowers of ... twenty flowers and the petals of the different species are ... stand out based on the contrasting colours of their bulbous ...
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5Novel type of bird pollination mechanism discovered in South America 2Mediterranean fish stocks show steady decline 2
... be enough to cool a hot temper, at least for a ... people who drank a glass of lemonade sweetened with sugar acted ... people who consumed lemonade with a sugar substitute. Researchers believe ... found in the bloodstream that provides energy for the brain. ...
... shows that anti-microbial medications are a common cause of ... (ALF), with women and minorities disproportionately affected. While ALF ... is unlikely; however liver transplantation offers an excellent survival ... published in the December issue of Hepatology , ...
... Washington, D.C. - U.S Energy Secretary Steven Chu today ... time to 57 innovative research projects - using computer ... would be impossible or impractical in the natural world. ... equal to 135,000 quad-core laptops, the research could, for ...
Cached Biology News:Researchers find link between sugar, diabetes and aggression 2Researchers find link between sugar, diabetes and aggression 3Researchers find link between sugar, diabetes and aggression 4Study finds anti-microbials a common cause of drug-induced liver injury and failure 2Could 135,000 laptops help solve the energy challenge? 2Could 135,000 laptops help solve the energy challenge? 3Could 135,000 laptops help solve the energy challenge? 4
... Edited by John M. Walker (1996) ... successful analytical techniques for studying proteins ... protocol contains detailed, step-by-step instruction, timesaving ... and comprehensive lists of reagents and ...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Human/Mouse/Rat Keap1 MAb (Clone 333116) Protein Family: Transcription Factor Regulators...
... 4503277 Accession Number: NP_001912.1 ... the nucleotide substrate for thymidylate synthetase. ... O = dUMP + NH 3 ... the Diseases: Benign Tumor; Leukemia; Escherichia ...
Biology Products: